Featured News

The Celiac Disease Foundation’s article, “New Legislation Aims to Extend Nutrition Care to Chronic Conditions” was featured in Future of Personal Health.

Patients Who Have Participated In a Celiac Disease Clinical Trial Needed for 2021 Patient Education & Advocacy Summit.

A new intensive study confirms that people with celiac disease are frequently exposed to gluten in food.

A new Alcohol and Tobacco Tax and Trade Bureau (TTB) ruling released October 13 allows a gluten-free label on spirits distilled from gluten-containing grains.

One of our most important research investments over the last several years has been in iCureCeliac®, the nation’s celiac disease patient registry. This month, researchers published three important studies that used iCureCeliac® as the data source.

Researchers from Takeda Pharmaceuticals and the Celiac Disease Foundation presented a study which concluded that despite gluten-free diet adherence, many patients with celiac disease still have symptoms that substantially impact their lives.

A study led by Columbia University and Celiac Disease Foundation researchers examined probiotic use among celiac disease patients and was an Outstanding Poster Presenter recipient at the 2020 ACG Annual Scientific Meeting.

The following study, which examines the prevalence of dermatitis herpetiformis (DH), was made possible by the Foundation’s iCureCeliac® patient registry.

The Celiac Disease Foundation is proud to partner with Mediaplanet for their Morning Nutrition campaign.

The Foundation is pleased to announce its partnership with Provention Bio to provide clinical trial recruitment for its Phase 2b PROACTIVE Celiac Study for PRV-015 (an anti-interleukin-15 monoclonal antibody).